

Silo Pharma, Inc. (SILO)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001514183

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company's lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release

ketamine-based loaded implant for fibromyalgia and chronic pain relief.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 90.5						
Gross profitability		0.4%	32.2%	92.2	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		5.8%	(6.6%)	88.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 49.6						
Twelve-month failure probability		3.32%	0.07%	93.5	248	2026-06-30
Altman Z double-prime		(1.23)	(0.31)	42.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		11.36x	2.96x	13.2	839	2025-12-31
Growth and financing, sleeve percentile 81.3						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(13.2%)	2.1%	73.3	704	2025-12-31
Net share issuance, one year		215.9%	2.5%	89.3	634	2026-03-27


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 215.9%
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Distress	CHS probability 3.315400%; universe top-decile threshold 1.068854%

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
347	Fortress Biotech, Inc. (FBIO)	93.6	E	fortress balance sheet
348	Fortress Biotech, Inc. (FBIOP)	93.6	E	fortress balance sheet
349	Co-Diagnostics, Inc. (CODX)	94.1	E	dilution, short runway, fortress balance sheet
350	Kyntra BIO, Inc. (KYNB)	94.3	E	
351	Celularity Inc. (CELU)	94.6	E	short runway, late filer
352	Silo Pharma, Inc. (SILO) <	94.9	E	dilution, degenerate inputs, distress
353	VivoSim Labs, Inc. (VIVS)	95.1	E	dilution, short runway, late filer
354	ALX Oncology Holdings Inc. (ALXO)	95.4	E	dilution, short runway, degenerate inputs, fortress balance sheet
355	Biomerica Inc. (BMRA)	95.7	E	short runway
356	Bolt Biotherapeutics, Inc. (BOLT)	95.9	E	short runway, distress
357	Pfizer Inc. (PFE)	96.2	E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(76.0%)	8.0%	4
Distance from 52-week high	(86.0%)	(31.4%)	5
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	2.12	0.28	97
Sales to price	0.03	0.31	11
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.64)	(0.14)	4

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$3.3M
Operating cash flow, four quarters	-\$3.3M
Months of runway	11.8
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$84,080

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$27,807	2025-12-31	2026-03-27	10-K	0001213900-26-035576
2	assets	us-gaap:Assets	\$7.6M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
3	net income	us-gaap:NetIncomeLoss	-\$4.2M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$4.7M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
5	assets	us-gaap:Assets	\$7.4M	2024-12-31	2026-03-27	10-K	0001213900-26-035576
6	current assets	us-gaap:AssetsCurrent	\$7.4M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
7	current liabilities	us-gaap:LiabilitiesCurrent	\$650,183	2025-12-31	2026-03-27	10-K	0001213900-26-035576
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$19.5M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
9	operating income	us-gaap:OperatingIncomeLoss	-\$4.3M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
10	book equity	us-gaap:StockholdersEquity	\$6.3M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
11	liabilities	us-gaap:Liabilities	\$1.3M	2025-12-31	2026-03-27	10-K	0001213900-26-035576
12	operating income	us-gaap:OperatingIncomeLoss	-\$3.9M	2023-12-31	2025-03-28	10-K	0001013762-25-004139
13	interest expense	us-gaap:InterestExpense	\$4,869	2023-12-31	2024-03-25	10-K	0001213900-24-025615
14	revenue	us-gaap:Revenues	\$72,102	2025-12-31	2026-03-27	10-K	0001213900-26-035576
15	revenue	us-gaap:Revenues	\$72,102	2024-12-31	2026-03-27	10-K	0001213900-26-035576
16	revenue	us-gaap:Revenues	\$72,102	2023-12-31	2025-03-28	10-K	0001013762-25-004139
17	revenue	us-gaap:Revenues	\$40,923	2020-12-31	2021-05-17	10-K/A	0001213900-21-026679
18	assets	us-gaap:Assets	\$7.7M	2023-12-31	2025-03-28	10-K	0001013762-25-004139
19	assets	us-gaap:Assets	\$11.6M	2022-12-31	2024-03-25	10-K	0001213900-24-025615
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	14,166,593	2026-03-27	2026-03-27	10-K	0001213900-26-035576
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,484,456	2025-03-26	2025-03-28	10-K	0001013762-25-004139